IP Library Granted Patent US 9,078,880
Granted Patent B2
US 9,078,880 · App. 13/381,995 · Granted Jul 14, 2015

Cytoprotective agent

Inventors: Kazuo Honda (Tokyo, JP); Terumasa Hashimoto (Tokyo, JP); Keita Shibata (Tokyo, JP); Keiko Hasegawa (Fuchu, JP); Keiji Hasumi (Fuchu, JP)
Assignees: National University Corporation Tokyo University of Agriculture and Technology; TMS Co., Ltd.; Showa University
A61K31/407C07D491/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,078,880
App. No.
13/381,995
Granted
Jul 14, 2015
Kind
B2
Abstract

Disclosed is a cytoprotective agent for use with respect to ischemic damage, including as an active ingredient a triprenyl phenol compound represented by the following general formula (I), wherein X is —CHY—C(CH 3 ) 2 Z, Y and Z are each independently —H or —OH, or jointly form a single bond, and R represents a hydrogen atom or a substituent with a molecular weight of 1000 or less.

Claims (10)

1. A method of treatment of cerebral hemorrhagic infarction, comprising the step of administering a drug containing a triprenyl phenol of formula (II) or formula (III) to a patient affected by cerebral hemorrhagic infarction:

wherein X 1 , X 2 and X 3 are each independently —CHY—C(CH 3 ) 2 Z; Y and Z are each independently —H or —OH, or jointly form a bond, and R 1 is selected from among any one of the following (A) through (C):

(A) a residue of an amino compound selected from the group consisting of a natural amino acid, a D-isomer of a natural amino acid, and a compound derived by replacing a carboxy group in a natural amino acid, or a D-isomer of a natural amino acid, with a hydrogen atom, a hydroxy group, or a hydroxymethyl group, from which one amino group has been removed, with the proviso that R 1 is not hydroxymethyl;

(B) an aromatic group having at least one selected from the group consisting of a carboxy group, a hydroxy group, a sulfonic group and a secondary amino group as a substituent or a part of a substituent, or an aromatic group that contains a secondary amino group and may contain a nitrogen atom; and

(C) an aromatic amino acid residue represented by the following formula (II-1)

wherein, in formula (II-1), n is 0 or 1, and R 3 is at least one substituent selected from the group consisting of a hydroxy group, a carboxy group, and a C1 to C5 alkyl group, wherein R 3 may be present or absent; and

wherein, in formula III, R 2 and the two nitrogens to which it is attached are derived from a diamine selected from the group consisting of: a natural amino acid with two amino groups; a D-isomer of a natural amino acid with two amino groups; a compound derived from a natural amino acid with two amino groups by replacing a carboxy group with a hydrogen atom, a hydroxy group, or a hydroxymethyl group; a compound derived from a D-isomer of a natural amino acid with two amino groups by replacing a carboxy group with a hydrogen atom, a hydroxy group, or a hydroxymethyl group; compounds having the formula H 2 N—CH(COOH)—(CH 2 ) n —NH 2 wherein n is an integer from 0 to 9; and compounds having the formula H 2 N—CH(COOH)—(CH 2 ) m —S p —(CH 2 ) q —CH(COOH)—NH 2 wherein m, p and q are each independently an integer from 0 to 9.

2. The method of treatment of cerebral hemorrhagic infarction according to claim 1 , wherein the triprenyl phenol compound is SMTP-7.

3. The method of treatment of cerebral hemorrhagic infarction according to claim 1 , wherein the patient is a patient with respect to whom treatment with a thrombolytic drug is contraindicated.

4. The method of treatment of cerebral hemorrhagic infarction according to claim 3 , wherein the triprenyl phenol compound is SMTP-7.

Assignments (6)
CHANGE OF NAME Recorded Dec 4, 2024
From: JI XING PHARMACEUTICALS HONG KONG LIMITED
To: CORXEL PHARMACEUTICALS HONG KONG LIMITED
Reel/Frame 069491/0774 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2024
From: BIOGEN MA INC.
To: JI XING PHARMACEUTICALS HONG KONG LIMITED
Reel/Frame 066379/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2021
From: TMS CO., LTD.
To: BIOGEN MA INC.
Reel/Frame 057534/0699 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE:TMS CO., LTD.10, 211 MOMTURA, INAGI-SHITOKYO 206-0804, JAPAN PREVIOUSLY RECORDED ON REEL 041584 FRAME 0068. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE:TMS CO., LTD.10, 211 MOMURA, INAGI-SHITOKYO 206-0804, JAPAN. Recorded Apr 24, 2017
From: NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLGY; SHOWA UNIVERSITY
To: TMS CO., LTD.
Reel/Frame 042318/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2017
From: NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY; SHOWA UNIVERSITY
To: TMS CO., LTD.
Reel/Frame 041584/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2012
From: HONDA, KAZUO; HASHIMOTO, TERUMASA; SHIBATA, KEITA; HASEGAWA, KEIKO; HASUMI, KEIJI
To: NATIONAL UNIVERSITY CORPORATION TOKYO; TMS CO., LTD.; SHOWA UNIVERSITY
Reel/Frame 027470/0659 →
Priority Claims (1)
JP 2009-160278 · Jul 6, 2009 · national
Continuity (1)
Related Publication 20120135996A1 · May 31, 2012